Fourth-gen Mini gets a soft-top variant► Three petrol engines, but no manual► Still as fun and stylish as ever? Despite being a country renowned for such bleak weather, the UK is one of the biggest ...

Novo Nordisk A/S today announced 2024 earnings ... If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare ...

LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk (NVO) forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors ...

That haul helped Novo’s total sales for 2024 grow 26% at constant currencies to 290.4 billion kroner (nearly $41 billion), contributing to operating profits of 128.3 billion kroner ($18 billion ...

Novo Nordisk Q4 sales rose 30% to around $12 billion. GLP-1 diabetes sales grew 12% to DKK42.2 billion, while obesity drug sales surged 91% to DKK 21.4 billion. On Wednesday, Novo Nordisk A/S NVO ...

Share Buyback Program: DKK20 billion concluded. Novo Nordisk AS (NYSE:NVO) reported a strong 26% sales growth and 26% operating profit growth for 2024. The company expanded its patient reach ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team of analysts issues a “Double Down” stock ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other ...

Dividend Increase: 21% increase to DKK11.40 per share. Share Buyback Program: DKK20 billion concluded. Novo Nordisk AS (NYSE:NVO) reported a strong 26% sales growth and 26% operating profit growth for ...

LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk (NYSE:NVO) forecast slower growth this year after Wegovy sales more than doubled in the fourth quarter, with analysts and investors ...